Clinical Trial

Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

Study acronym: MetroWilms
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multicenter, interventional, non-randomized study among patients with a relapsed or refractory Wilms tumor. The study will aim to assess efficacy of metronomic chemotherapy, in terms of disease control after two cycles of metronomic chemotherapy.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-05-18; most recent amendment 2026-03-16.
Status change: Not Yet Recruiting → Recruiting 2023-02-13
Trial Details
NCT Number NCT05384821
Lead Sponsor Centre Oscar Lambret
Conditions Wilms Tumor
Enrollment 28 participants
Start Date 2022-09-14
Primary Completion 2028-05 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-18